NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
23155-0548-41 | 23155-0548 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 9, 2015 | In Use | |
23155-0548-42 | 23155-0548 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 9, 2015 | In Use | |
23155-0549-31 | 23155-0549 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jun 15, 2012 | In Use | |
23155-0550-31 | 23155-0550 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 9, 2015 | In Use | |
23155-0686-31 | 23155-0686 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 25, 2022 | In Use | ||
00143-9642-01 | 00143-9642 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jun 3, 2013 | In Use | ||
67108-3565-09 | 67108-3565 | Mesna | Mesnex | 400.0 mg/1 | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Oral | Mar 21, 2002 | In Use | |
00143-9701-01 | 00143-9701 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec 20, 2010 | In Use | |
51144-0050-01 | 51144-0050 | Brentuximab vedotin | Adcetris | 50.0 mg/10.5mL | Immunotherapy | Drug Antibody Conjugate | CD30 | Intravenous | Aug 25, 2011 | In Use | |
00143-9702-01 | 00143-9702 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec 20, 2010 | In Use | |
47335-0930-21 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
00046-1100-52 | 00046-1100 | Estrogens, Conjugated | Premarin | 0.3 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov 11, 2019 | In Use | ||
31722-0525-90 | 31722-0525 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug 1, 2010 | In Use | |
68788-6440-04 | 68788-6440 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 21, 2017 | In Use | |
47335-0930-74 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
00143-9771-06 | 00143-9771 | Ondansetron Hydrochloride and Dextrose | Ondansetron Hydrochloride and Dextrose | 32.0 mg/50mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Aug 4, 2009 | In Use | |
33358-0512-30 | 33358-0512 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 2, 2014 | In Use | |
00143-9830-01 | 00143-9830 | Methotrexate | Methotrexate | 1.0 g/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | Apr 25, 2017 | In Use | |
52959-0220-06 | 52959-0220 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 16, 2017 | In Use | |
24338-0050-08 | 24338-0050 | Carmustine | Gliadel | 7.7 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Intracavitary | Dec 13, 2012 | In Use | |
24535-0831-01 | 24535-0831 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Aug 20, 2017 | In Use | |
24658-0704-05 | 24658-0704 | ESTRADIOL | ESTRADIOL | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 10, 2021 | In Use | ||
24658-0704-90 | 24658-0704 | ESTRADIOL | ESTRADIOL | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 10, 2021 | In Use | ||
24724-0030-03 | 24724-0030 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 15, 2011 | In Use | ||
55513-0023-01 | 55513-0023 | Darbepoetin alfa | Aranesp | 60.0 ug/.3mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Feb 18, 2011 | In Use |
Found 11120 results — Export these results